Earnings Alerts

Unveiling Sartorius Stedim Biotech (DIM) Earnings: A Deep Dive into 9M Revenue and Underlying Ebitda Results

By October 19, 2023 No Comments
  • Sartorius Stedim Biotech has reported a 9-month revenue of EU2.07 billion.
  • The company has received orders worth EU1.76 billion during this period.
  • The underlying Ebitda for the company stands at EU594.0 million.
  • There have been 9 buys, 3 holds, and 3 sells of the company’s shares.

A look at Sartorius Stedim Biotech Smart Scores

FactorScoreMagnitude
Value2
Dividend1
Growth4
Resilience3
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Sartorius Stedim Biotech is a company that develops and manufactures laboratory technologies and equipment for the pharma and food industries, as well as for public research institutes and laboratories. According to the Smartkarma Smart Scores, its long-term outlook is generally positive. The company scores particularly well in terms of growth, with a score of 4 out of 5. It also scores above average for resilience and momentum, with 3 out of 5 in both categories. Despite its relatively lower score of 2 out of 5 for value, the long-term outlook for Sartorius Stedim Biotech is generally positive.

The company has been steadily increasing its presence in the pharmaceutical and food industries, and its strong scores for growth, resilience, and momentum indicate that it is well-positioned to continue to do so in the future. Its relatively lower score for value may be due to the challenges it faces in the competitive landscape, but its overall outlook is still good. Sartorius Stedim Biotech looks set to continue its growth and success in the years to come.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars